Skip to content

Exelixis

US · EXEL #1156 by market cap Listed 1970
64.63 -1.20 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Fair Value how this is computed

Near fair value
38.74 fair value ≈ 77.77 116.81
  • Implied fair-value range of 38.74-116.81, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -16.9% below the average-multiple fair value of 77.77.

Valuation each multiple against its own 5-year range

P/B ratio 8.60 Expensive vs history 98th percentile
5-year average 3.96 · #454 of 511 in Biotechnology
P/E ratio 19.35 Cheap vs history 32nd percentile
5-year average 27.98 · forward 15.87 · #45 of 74 in Biotechnology
P/S ratio 6.32 Expensive vs history 98th percentile
5-year average 4.40 · forward 5.63 · #150 of 392 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Exelixis (EXEL) 15.77B 19.35 8.60 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value66.09 Economic moatNarrow UncertaintyHigh

Trading 2.3% below Morningstar's fair value estimate.

Fair value

Exelixis Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a high uncertainty rating.

The firm's balance sheet bolsters our valuation estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its debt to EBITDA ratio of 0.2, which falls in the bottom 10% compared with peers globally. Without much debt relative to assets, this company should exhibit high resilience should the global economy weaken; if not, the company could raise debt and invest in the business or return capital to shareholders. This benefit contributes to our balanced fair value estimate.

Conversely, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, falls in the bottom 30% compared with peers globally. This could imply a planned dividend cut or relatively high share price, which further promotes our neutral price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.

Exelixis discussion 0 comments

Add a comment